Colorado School of Public Health, Aurora, Colorado, USA.
U.S. Department of Agriculture, Economic Research Service, Washington, District of Columbia, USA.
Foodborne Pathog Dis. 2021 Nov;18(11):812-821. doi: 10.1089/fpd.2021.0028. Epub 2021 Sep 24.
Foodborne illness is a continuing public health problem in the United States. Seven pathogens-, , Shiga toxin-producing O157, , nontyphoidal , norovirus, and are estimated to cause >90% of the foodborne illnesses, hospitalizations, and deaths attributed to 31 known pathogens. The purpose of this article was to inform estimates of the cost of hospitalizations associated with these pathogens using National Inpatient Survey data from January 2012 through September 2015. The article explored two methodological issues. First, is it more appropriate to use hospitalizations identified using principal or all diagnosis codes when estimating cost? Second, should pathogen-specific or overall mean cost estimates be used? After excluding because of low sample size, the remaining six pathogens included in the analysis were associated with 17,102 hospital discharge records. Of these 55% have the pathogen listed as a principal diagnosis (FBP-PD), ranging from 6% for to 68% for nontyphoidal . The mean per-case cost of records with the pathogen listed as a secondary diagnosis (FBP-SD) was 2.7 times higher than FBP-PD. FBP-SD were also more severe than FBP-PD with longer lengths of stay, increasing loss of function, and increasing risk of mortality. Severity was the main driver of cost. We also found severity of illness and cost of hospitalizations vary by pathogen. Based on identifying cases with a pathogen in either FBP-PD or FBP-SD, we found mean per-case hospitalization cost across the six pathogens included in this study was $17,515, ranging from $11,552 for to $34,206 for norovirus. In summary, if only FBP-PD cases were used to estimate cost, estimates would likely underestimate hospitalization costs among those cases with a pathogen-specific diagnosis. Because these foodborne pathogens varied in severity of illness, the mean cost of hospitalizations also varied significantly by pathogen.
食源性疾病是美国持续存在的公共卫生问题。据估计,有 7 种病原体(产志贺毒素大肠杆菌 O157:H7、单核细胞增生李斯特菌、弯曲杆菌、沙门氏菌、创伤弧菌、金黄色葡萄球菌和诺如病毒)导致了 90%以上归因于 31 种已知病原体的食源性疾病、住院和死亡病例。本文旨在利用 2012 年 1 月至 2015 年 9 月期间的国家住院患者调查数据,为与这些病原体相关的住院费用提供估计值。本文探讨了两个方法问题。首先,在估计成本时,使用主要诊断代码或所有诊断代码识别的住院治疗是否更为合适?其次,是否应使用病原体特异性或总体平均费用估计值?由于样本量较小而排除 后,分析中包括的其余六种病原体与 17,102 份出院记录相关。在这些记录中,有 55%的记录将病原体列为主要诊断(FBP-PD),范围从 产志贺毒素大肠杆菌 O157:H7 的 6%到非伤寒沙门氏菌的 68%。将病原体列为次要诊断(FBP-SD)的记录的每例费用平均比 FBP-PD 高 2.7 倍。FBP-SD 比 FBP-PD 更严重,住院时间更长,功能丧失更多,死亡风险更高。严重程度是成本的主要驱动因素。我们还发现病原体的严重程度和住院费用因病原体而异。根据在 FBP-PD 或 FBP-SD 中识别出的病例,我们发现本研究中包括的六种病原体的每例平均住院费用为 17,515 美元,范围从产志贺毒素大肠杆菌 O157:H7 的 11,552 美元到诺如病毒的 34,206 美元。总之,如果仅使用 FBP-PD 病例来估计成本,那么对于具有特定病原体诊断的病例,估计值可能会低估住院费用。由于这些食源性病原体的疾病严重程度不同,住院费用的平均值也因病原体而异。